Author

Paul Moreton

Observed names: Moreton, P, Moreton, Paul, P. Moreton

Observed institutions: Leeds General Infirmary, University of Leeds, Karolinska University Hospital, Leeds Teaching Hospitals NHS Trust, Aberdeen Royal Infirmary, St James's University Hospital, Manchester Royal Infirmary, Stobhill Hospital, Nottingham City Hospital, University of Oxford, Heartlands Hospital, Royal Marsden Hospital, Addenbrooke's Hospital, Mid Yorkshire Hospitals NHS Trust, Pinderfields Hospital, Takeda Oncology (United States), University College London

OpenAlex ID: A5060073254

Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

2005 · Paul Moreton, Ben Kennedy, et al. · Journal of Clinical Oncology · 419

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

2004 · Geoff Hale, Peppy Rebello, et al. · Blood · 182

PDF

Minimal residual disease is an independent predictor for 10-year survival in CLL

2016 · Marwan Kwok, Andy C. Rawstron, et al. · Blood · 136

PDF

Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study

2014 · Peter Hillmen, John G. Gribben, et al. · Journal of Clinical Oncology · 122

PDF

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia

2003 · Andy C. Rawstron, Ben Kennedy, et al. · Blood · 66

Assessment of Bone Marrow Response in Waldenström's Macroglobulinemia

2009 · Abraham M. Varghese, Andy C. Rawstron, et al. · Clinical Lymphoma & Myeloma · 52

Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

2024 · Nigel H. Russell, Charlotte Wilhelm-Benartzi, et al. · Journal of Clinical Oncology · 49

Alemtuzumab therapy in B-cell lymphoproliferative disorders

2003 · Paul Moreton, Peter Hillmen · Seminars in Oncology · 40

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

2010 · Peter Hillmen, John G. Gribben, et al. · Blood · 36

B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle

2007 · Fiona Bennett, Andy Rawstron, et al. · British Journal of Haematology · 35

PDF

Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia

2008 · Claes Karlsson, Jeanette Lundin, et al. · British Journal of Haematology · 31

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

2019 · Marwan Kwok, Ceri Oldreive, et al. · Blood · 28

PDF

Interim Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

2005 · Hazem Sayala, Paul Moreton, et al. · Blood · 18

The development of targeted chemotherapy for CNS lymphoma?a pilot study of the IDARAM regimen

2004 · P. Moreton, G. J. Morgan, et al. · Cancer Chemotherapy and Pharmacology · 17

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

2009 · Peter Hillmen, John G. Gribben, et al. · Blood · 13

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

2006 · Hazem A. Sayala, Paul Moreton, et al. · Blood · 10

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

2012 · Alan K Burnett, Nigel H. Russell, et al. · Blood · 9

Achieving a MRD negative response after alemtuzumab for CLL is the best predictor for prolonged survival

2003 · Paul Moreton, D. B. Kennedy, et al. · Blood · 7

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

2010 · Abraham M Varghese, Hazem A. Sayala, et al. · Blood · 6

Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.

2007 · Hazem A. Sayala, Paul Moreton, et al. · Blood · 6

Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia

2014 · Marwan Kwok, Andy Rawstron, et al. · The Lancet · 5

PDF

Simultaneous acute myeloid leukaemia and de novo acute hepatitis B: A novel management strategy

2010 · Christopher Parrish, Paul Moreton, et al. · Leukemia Research · 4

The correlation between the eradication of minimal residual disease (MRD) following alemtuzumab for CLL and overall survival

2004 · P. Moreton, B. Kennedy, et al. · Journal of Clinical Oncology · 2

Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

2018 · Allison Gathany, Robyn M. Scherber, et al. · Blood · 1

Rituximab Plus Chlorambucil (r-chlorambucil) as First-line Treatment for Chronic Lymphocytic Leukaemia (cll): Final Analysis of an Open-label Phase Ii Study

2011 · Hillmen, P, Gribben, JG, et al. · UCL Discovery (University College London) · 1

Works count: 39

Citation count: 1,296

H-index: 14

I10-index: 16